|
Patent landscape, scope, and claims summary: |
US Patent 9,062,106 (Adalimumab Galactosylation) Claim Scope and US Patent Landscape
US 9,062,106 claims methods to increase the galactosylation (specifically galactose-containing fucosylated biantennary N-linked glycans) of recombinantly expressed adalimumab by supplementing culture media with manganese (Mn) at defined micromolar levels and galactose (Gal) at defined millimolar levels, with dependent claim fallbacks on specific salts, cell types, process parameters, and target glycoform percentages. The claims are tightly anchored to the combination of Mn and Gal supplementation ranges, and to the adalimumab product glycosylation outcome as measured by specific glycoform families.
What does US 9,062,106 claim to do, in plain patent terms?
Core independent claim concept (Claim 1):
- A process for producing adalimumab with higher galactosylation by:
- Supplementing the expression media used for a recombinantly expressed adalimumab
- With manganese to reach 0.2–100 μM
- With galactose to reach 1–100 mM
- Resulting in higher galactosylation than the same recombinant adalimumab expressed in media without both Mn and Gal supplements.
Core independent claim concept (Claim 34):
- Similar to Claim 1, but explicitly includes culturing adalimumab-expressing cells in that supplemented media (method framed as Mn+Gal supplementation plus culturing in the defined media).
Claim 21 and onward anchor the outcome:
- At least 10% of total N-linked oligosaccharides on adalimumab are galactose-containing fucosylated biantennary glycans (NA1F + NA2F).
- Threshold-dependent fallbacks at 15% and 20% (Claims 22-23; Claim 50 sets “20%”).
Practical implication:
- The patent’s enforceability and product-by-product risk are driven by whether a competitor’s manufacturing process uses both Mn and Gal supplementation in the claimed concentration bands and yields the required NA1F+NA2F proportions.
What is the exact claim construction risk: Mn+Gal combination, ranges, and the “increased galactosylation” comparative requirement?
Key enforceability hinge: The claims require both:
- Mn in 0.2–100 μM
- Gal in 1–100 mM
- Increased galactosylation relative to an adalimumab control produced without Mn+Gal supplementation.
Range mapping for infringement and design-arounds
| Claim element |
Claimed range(s) (US 9,062,106) |
Dependent claim lock-ins |
| Manganese (Mn) in media |
0.2–100 μM |
Claims 6, 24-28 (sub-ranges 0.2–40; 40–100; 40–60; 50–80; 75–100; specific exemplars) |
| Galactose (Gal) in media |
1–100 mM |
Claims 7, 29-32 (sub-ranges 10–100; 1–60; 60–100; 10–60; specific exemplars) |
| Outcome metric |
Increased galactosylation vs. unsupplemented control |
Claim 1/34 comparative language |
| Glycan-family threshold |
NA1F+NA2F ≥10% (and later ≥15%, ≥20%) |
Claims 21-23; 48-50 |
Comparative language as a litigation lever
- The “increased as compared to” language means proof often centers on:
- A manufacturing comparison (Mn+Gal vs no Mn+Gal) at the process stage the patent targets; and/or
- Analytical evidence that the Mn+Gal process produces higher galactosylation.
- In practice, this can shift the evidentiary fight toward:
- Batch records, feed compositions, and sampling timepoints
- Glycan profiling results quantifying NA1F+NA2F
“Sufficient amount” ambiguity and how it cuts
- The claims repeatedly use “sufficient amount … to achieve a concentration in the media” at given bands. That tends to narrow “sufficient” to measurable concentration endpoints rather than qualitative “effective amount” (which competitors sometimes exploit). Concentration achievement is the measurable infringement gate.
Which manganese supplements and galactose supplements are specifically covered?
Mn species coverage (dependent claims):
- Claim 2: biologically acceptable manganese salt.
- Claim 3: manganese (II) chloride (MnCl₂).
Gal species coverage (dependent claims):
- Claim 4: biologically acceptable galactose-containing compound.
- Claim 5: D-(+)-galactose.
Implication for landscape risk:
- The independent claims cover Mn and Gal supplementation at concentration levels regardless of salt/form unless narrowed by a dependent claim. In a challenge, the presence of “biologically acceptable” and the identification of Mn and Gal forms may matter more for dependent claim targets (Claims 2-5, 35-38).
What cell culture, process format, and duration limitations matter?
The patent includes dependent claims that carve out the manufacturing context:
Media types
- Claim 9/42: media selected from:
- chemically defined (CD) cell culture media
- hydrolysate-based media
Suspension culture
- Claim 10: suspension culture.
Cell adaptation
- Claim 11: mammalian cell adapted for growth in CD media.
Specific cell lines
- Claim 12: CHO cells
- Claim 13: NS0 cells
Culture duration
- Claim 14: at least 4 days
- Claim 15/47: up to 12 days
Fed-batch and bioreactors
- Claim 19/63: fed-batch process
- Claim 20/65: bioreactor
Recovery and purification
- Claim 16-17: recover adalimumab; purify.
- Claim 18/53: quantify specific glycoforms (NA1F/NA2F and/or NGA2F / NGA2F-GlcNAc).
Implication:
- If a competitor’s manufacturing platform uses different cell lines (not CHO/NS0), different culture modes (not fed-batch/bioreactor), or duration outside “at least 4 days” to “up to 12 days,” dependent claims narrow. The independent claims remain broader because they do not require a particular cell line unless attacked via claim construction or prosecution history estoppel (not provided here).
What glycan outcome is required: NA1F+NA2F percentage thresholds and how they affect infringement?
Outcome definition in dependent claims
- Claim 21: at least 10% of total N-linked oligosaccharides are galactose-containing fucosylated biantennary (NA1F + NA2F).
- Claim 22: at least 15%
- Claim 23: at least 20%
Quantification-related claims
- Claim 18/53: quantifies NA1F/NA2F and/or agalactosylated fucosylated biantennary forms (NGA2F and NGA2F-GlcNAc).
Litigation relevance
- These thresholds are not merely academic; they function as a definitional metric for the “galactosylation level” and convert a biological property into a quantifiable analytics claim target.
- If a generic or biosimilar manufacturing process yields adalimumab with NA1F+NA2F below the threshold, it may avoid infringement of dependent claims. But it could still infringe the independent “increased galactosylation” if “increased” is met relative to the unsupplemented control.
How does US 9,062,106 split into claim strategy layers?
Layer 1: Independent method frame (broadest)
- Claim 1 and Claim 34: Mn (0.2–100 μM) + Gal (1–100 mM) supplementation, and increased galactosylation relative to unsupplemented controls.
Layer 2: Dependent “species and endpoints”
- Mn salt and Gal compound-specific dependent claims (Claims 2-5, 35-38)
- Specific glycoform outcome percentages (Claims 21-23, 48-50)
Layer 3: Dependent process constraints
- Media type (CD vs hydrolysate), suspension vs fed-batch, cell lines (CHO/NS0), duration windows, bioreactor context, and recovery/purification.
Practical meaning
- For a manufacturing process to clearly avoid infringement, it must either:
- avoid using the Mn and Gal at those concentration bands simultaneously; and/or
- avoid producing increased galactosylation relative to the unsupplemented control; and/or
- specifically manage glycoform outcomes to avoid the NA1F+NA2F thresholds for dependent claims.
What patent landscape would US 9,062,106 likely sit within for adalimumab glycoengineering?
US 9,062,106 is a glycoengineering manufacturing patent: it claims culture media supplementation to drive an N-glycan profile shift. The broader competitive landscape for adalimumab “higher galactosylation / altered sialylation/aggregation risk” technologies typically clusters into:
- culture media supplementation strategies (carbohydrate donors and metal ions)
- cell line and process platform optimization (CHO/NS0, fed-batch, bioreactors)
- analytical characterization and control strategies (glycan profiling)
- downstream purification and formulation interplay (less directly claimed here)
However, a complete critical analysis of “the patent landscape” requires the actual bibliographic data for US 9,062,106 and citations/pedigree. The user prompt does not include:
- filing date, priority date, assignees, or publication number
- the specification’s description of prior art and related families
- claim-by-claim history (continuations/divisionals)
- the complete US patent family membership
- any co-pending related patents covering the same manufacturing knobs
- Orange Book or FDA listing status, which is not applicable to a biologic but is sometimes mistakenly mapped in competitive analyses
- any litigation docket or licensing deals tied to this specific patent
Per the operating constraints, without that data, producing an accurate multi-patent landscape analysis is not possible.
Accordingly, the analysis below is limited to claim-scope mechanics and enforceability levers based on the claim text provided.
How strong is the claim suite as drafted: breadth vs susceptibility to design-around?
Strength factors
-
Dual-input concentration coupling (Mn+Gal)
- Competitors must manage both variables. Avoiding one may not be enough if the other remains within range and the process can still produce increased galactosylation.
-
Measured concentration endpoints
- “Sufficient amount … to achieve … concentration” narrows the ambiguity and improves enforceability with batch/feed records.
-
Glycoform threshold fallbacks
- NA1F+NA2F quantification provides an objective metric for dependent claims.
Vulnerability factors
-
Comparative “increased” wording
- Comparative controls can be litigated: what is the appropriate “control” formulation/process, and does it match manufacturing conditions except Mn+Gal?
-
Biological variability
- Even within identical ranges, glycosylation can shift with upstream process conditions (pH, temperature, feed timing, residence time, cell growth state). That variability is often where defendants attack causal linkage.
-
Dependent claim reliance
- If a competitor’s process yields increased galactosylation but does not meet a specific NA1F+NA2F threshold, it may defeat dependent claims, leaving only the broad independent “increased” hook.
What would a generic or biosimilar manufacturer need to avoid to reduce US 9,062,106 risk?
For a process-containment strategy:
- Avoid achieving both:
- Mn 0.2–100 μM
- Gal 1–100 mM
in the relevant media stages.
- If Mn is used, manage it outside claimed bands or omit Gal within claimed bands, and vice versa.
For an analytics containment strategy:
- Keep NA1F+NA2F below:
- 10% (to avoid Claims 21/48)
- 15% (to avoid Claims 22/49)
- 20% (to avoid Claims 23/50)
For a litigation-proofing strategy:
- Ensure batch records and feed calculations demonstrate that media did not reach the claimed concentration targets during the period that controls galactosylation.
Key claim-by-claim “coverage map” (what a competitor’s process would have to do)
| Feature |
Claims directly implicating it |
| Supplement expression media with Mn 0.2–100 μM |
1, 6, 24-28; 34, 39, 54-58 |
| Supplement expression media with Gal 1–100 mM |
1, 7, 29-32; 34, 40, 59-62 |
| Use Mn biologically acceptable salt |
2, 35 |
| Use MnCl₂ specifically |
3, 36 |
| Use biologically acceptable galactose compound |
4, 37 |
| Use D-(+)-galactose |
5, 38 |
| Defined Mn/Gal concentration pairs |
8, 41 |
| Media is CD and/or hydrolysate-based |
9, 42 |
| Suspension culture |
10 |
| CHO or NS0 |
12-13, 44-45 |
| Culture duration 4+ days, up to 12 days |
14-15, 46-47 |
| Fed-batch and bioreactor context |
19-20, 63-65 |
| Recover and purify the product |
16-17, 51-52 |
| Quantify NA1F/NA2F and/or NGA2F/NGA2F-GlcNAc |
18, 53 |
| Outcome: NA1F+NA2F ≥10%, 15%, 20% |
21-23, 48-50 |
Key Takeaways
- US 9,062,106 is a manufacturing glycoengineering patent targeting increased galactosylation of recombinantly expressed adalimumab by co-supplementing culture media with Mn (0.2–100 μM) and Gal (1–100 mM).
- Dependent claims narrow further to specific Mn salts (MnCl₂) and Gal forms (D-(+)-galactose), specific process settings (CD vs hydrolysate, suspension, CHO/NS0, fed-batch/bioreactor), and objective glycoform thresholds (NA1F+NA2F at ≥10%, ≥15%, ≥20%).
- Main infringement and freedom-to-operate pressure points are:
- whether a process achieves both Mn and Gal concentration bands
- whether the process yields increased galactosylation relative to an appropriate unsupplemented control
- whether product analytics meet NA1F+NA2F percentage dependent thresholds.
FAQs
-
Does US 9,062,106 require using both Mn and Gal at the same time?
The claims require supplementing media with both manganese and galactose to reach the stated concentration ranges, and the increased galactosylation is compared to adalimumab produced in media without those supplements.
-
What specific glycans define the “galactosylation level” in dependent claims?
The dependent thresholds use galactose-containing fucosylated biantennary oligosaccharides, specifically NA1F + NA2F, measured as a percentage of total N-linked oligosaccharides.
-
Can a process avoid dependent claim infringement by keeping NA1F+NA2F below 20%?
It may avoid the dependent claim requiring at least 20% NA1F+NA2F, but it does not automatically avoid the independent claims if “increased galactosylation” is still achieved.
-
Are CHO and NS0 the only covered cell types?
CHO and NS0 are explicitly named in dependent claims. The independent claims, based on the provided text, are not limited to those specific cell lines.
-
Do the claims cover manganese salts other than manganese (II) chloride?
Yes. MnCl₂ is a dependent fallback (Claim 3/36). Claim 2/35 covers biologically acceptable manganese salts generally.
References (APA)
No citable sources were provided in the prompt beyond the claim text itself, and no publication/bibliographic details for US 9,062,106 (assignee, filing date, family members, prosecution history, or related art) were included.
More… ↓
⤷ Start Trial
|
